Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes

Journal Article · · The Journal of Experimental Medicine, 210(1):191-203
DOI:https://doi.org/10.1084/jem.20111843· OSTI ID:1060117

Using global liquid chromatography-mass spectrometry (LC-MS)-based proteomics analyses, we identified 24 serum proteins significantly variant between those with type 1 diabetes and healthy controls. Functionally, these proteins represent innate immune responses, the activation cascade of complement, inflammatory responses and blood coagulation. Targeted verification analyses were performed on 52 surrogate peptides representing these proteins with serum samples from an antibody standardization program cohort of 100 healthy control and 50 type 1 diabetic subjects, and 16 peptides were verified having very good discriminating power, with areas under the receiver operator characteristic curve ≥ 0.8. Further validation with blinded serum samples from an independent cohort (10 healthy control and 10 type 1 diabetic) demonstrated that peptides from platelet basic protein and C1 inhibitor achieved both 100% sensitivity and 100% specificity for classification of samples. The disease specificity of these proteins was assessed using serum from 50 age matched type 2 diabetic individuals, and a subset of proteins, particularly C1 inhibitor were exceptionally good discriminators between these two forms of diabetes. The panel of biomarkers distinguishing those with type 1 diabetes from healthy control and type 2 diabetes suggests dysregulated innate immune responses may be associated with the development of this disorder.

Research Organization:
Pacific Northwest National Laboratory (PNNL), Richland, WA (US), Environmental Molecular Sciences Laboratory (EMSL)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC05-76RL01830
OSTI ID:
1060117
Report Number(s):
PNNL-SA-89853; 40072; 46703
Journal Information:
The Journal of Experimental Medicine, 210(1):191-203, Journal Name: The Journal of Experimental Medicine, 210(1):191-203
Country of Publication:
United States
Language:
English

Similar Records

Redox regulation of m6A methyltransferase METTL3 in β-cells controls the innate immune response in type 1 diabetes
Journal Article · Sun Feb 25 23:00:00 EST 2024 · Nature Cell Biology · OSTI ID:2407043

New Onset Type 1 Diabetes Urine Metabolomics
Dataset · Mon Jul 22 00:00:00 EDT 2024 · OSTI ID:2405140

Association of Serum Bile Acid and Unsaturated Fatty Acid Profiles with the Risk of Diabetic Retinopathy in Type 2 Diabetic Patients
Journal Article · Thu Jul 13 00:00:00 EDT 2023 · Diabetes, Metabolic Syndrome and Obesity · OSTI ID:2470665